America considers the vaccine as the most effective weapon against Covid-19 strains, but the country's production capacity is very limited.

The global race to produce enough Vaccine Covid-19 for 7 billion people is about to become difficult.

The doctor is treating a Covid-19 patient at United Memorial Medical Center in Houston, Texas, in December last year.

Vaccine manufacturers like Pfizer, Moderna or Johnson & Johnson have to stretch their own huge needs globally with their first vaccine patterns.

But now it is not a possible choice, because companies have to race to complete the existing Vaccine Covid-19 orders but have a difficult situation in production.

The launch of the second generation vaccine will require factories to convert the lines that are manufacturing the first vaccine samples and in many cases, they even have to establish new production processes.

Interruption in production is said to be the biggest potential challenge for the Biden administration in the effort to end the Covid-19 pandemic.

P.1 strains, first discovered in Brazil and also spread to the US, are making similar concerns about whether they can resist some popular global vaccines today.

Biden government officials are trying to race with the time to find out how the way the spreads will change the vaccine strategy.

With vaccine manufacturers, they don't know how and when to prioritize the new generation vaccine, Stephen Ostroff, expert with more than 20 years of working at the American disease control and prevention center (

Preliminary data on Covid-19 vaccines are available in the US from Pfizer manufacturers, Moderna and Johnson & Johnson show that they can prevent the most worrying variations that have been known, though injections

However, companies still conducted updated research for their regimen, including alternatives for recalls, modifying vaccines or producing vaccines in accordance with a specific type of transaction.

Moderna, Pfizer and Astrazeneca are three of the manufacturers who tested the vaccine samples focused on specific strains.

But despite the early discussions with the authorities, Astrazeneca and Sanofi are still unlikely to become the first companies to successfully produce varancing vaccines if demand increased this year.

The original vaccine of Astrazeneca, widely used globally but not yet available in the US, is facing many difficulties in production and concerns about safety.

Some vaccine manufacturers provided to the US are trying to expand production capacity with support from the Government.

"The question is that companies who are self-risky compared to government support," said Nicole Lurie, officials leading urgent response efforts under the Ministry of Health and American Human Services under

The US government has deducted billions of dollars to buy hundreds of millions of vaccines from Pfizer, Moderna, J & J, Astrazeneca and Novavax.

After that, the road ahead will become blind.

Additional injections are the possible response option, but these added injections will significantly increase pressure on manufacturers.

"The good news is that the current vaccines create neutral antibodies to help fight the strains", a senior government official said.

This official said there are three feasible ways to deal with strains, including an immune system with an existing vaccine dose or with a specific vaccine dose with a variation or combining them into a diploid vaccine

The Biden administration is betting on the vaccination plan for the majority of the population before the strains spread widely and need to be used to a new vaccine.

"I think even when a vaccine variant is created through full tests, switching to using it also needs to be cautiously conducted," Lurie said.

All of the above poses one of the biggest challenges for US vaccine policy.

However, the Biden government needs to ensure the balance between the mission to protect the American people as promised and participate in global effort to defeat the virus before the strains become the world's largest problem, specializing in